Tags

Type your tag names separated by a space and hit enter

[ACT/AA polymorphism could duplicate the APOE*epsilon4-associated Alzheimer's disease risk].
Med Clin (Barc). 2004 Sep 04; 123(7):251-4.MC

Abstract

BACKGROUND AND OBJECTIVE

The association between the presence of the allele APOE*epsilon4 (apolipoprotein E) and sporadic Alzheimer disease (AD) has been long established. However, the possible influence of other genetic factors is still under debate. This study investigated the role of the a 1-antichymotrypsin (ACT) gene as a susceptibility factor for developing late-onset AD in the population of Navarra.

PATIENTS AND METHODS

The study group included 98 patients with late-onset AD and 188 control individuals 70-71 years of age. APOE*epsilon2,*epsilon3,*epsilon4 and ACT codon -17*A,*T polymorphisms were analyzed by PCR-RFLP. Statistical analyses were performed determining the chi-square test, using 2 x 2 contingency tables and logistic regression to calculate odds ratios.

RESULTS

APOE*epsilon4 allele frequency was significantly higher in AD patients than in controls (odds ratio [OR] = 3.02; 95% confidence interval [CI], 1.59-5.73; p < 0.001 in heterozygous carriers, and OR = 9.40; 95% CI, 1.84-64.43; p = 0.001 in homozygous individuals). We found no significant differences in the distribution of ACT polymorphisms between AD cases and controls. However, APOE*epsilon4 carriers had a 2.5-fold increased risk of developing AD in the presence of the ACT/AA genotype (OR = 10.13; 95% CI, 1.98-97.81; p < 0.001). The risk difference, however, did not reach statistical significance (p = 0.271).

CONCLUSIONS

APOE*epsilon4 heterozygous and homozygous carriers have a 3 and 9 times higher risk, respectively, of developing AD. We could not demonstrate an effect of ACT polymorphisms as a independent risk factor for this disease; however, the ACT/AA genotype seems to act as an additional susceptibility factor, duplicating the APOE*epsilon4-associated AD risk.

Authors+Show Affiliations

Hernández-Charro B
Servicio de Genética Médica, Hospital Virgen del Camino, Pamplona, Spain.
Moreno S
No affiliation info available
Valiente A
No affiliation info available
Manubens JM
No affiliation info available
Villar MD
No affiliation info available
Ramos-Arroyo MA
No affiliation info available

MeSH

AgedAged, 80 and overAlzheimer DiseaseApolipoproteins ECase-Control StudiesFemaleGene FrequencyGenotypeHumansLogistic ModelsMaleMiddle AgedOdds RatioPolymorphism, GeneticRisk Factorsalpha 1-Antichymotrypsin

Pub Type(s)

Comparative Study
English Abstract
Journal Article

Language

spa

PubMed ID

15482730

Citation

Hernández-Charro, Blanca, et al. "[ACT/AA Polymorphism Could Duplicate the APOE*epsilon4-associated Alzheimer's Disease Risk]." Medicina Clinica, vol. 123, no. 7, 2004, pp. 251-4.
Hernández-Charro B, Moreno S, Valiente A, et al. [ACT/AA polymorphism could duplicate the APOE*epsilon4-associated Alzheimer's disease risk]. Med Clin (Barc). 2004;123(7):251-4.
Hernández-Charro, B., Moreno, S., Valiente, A., Manubens, J. M., Villar, M. D., & Ramos-Arroyo, M. A. (2004). [ACT/AA polymorphism could duplicate the APOE*epsilon4-associated Alzheimer's disease risk]. Medicina Clinica, 123(7), 251-4.
Hernández-Charro B, et al. [ACT/AA Polymorphism Could Duplicate the APOE*epsilon4-associated Alzheimer's Disease Risk]. Med Clin (Barc). 2004 Sep 4;123(7):251-4. PubMed PMID: 15482730.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [ACT/AA polymorphism could duplicate the APOE*epsilon4-associated Alzheimer's disease risk]. AU - Hernández-Charro,Blanca, AU - Moreno,Sira, AU - Valiente,Alberto, AU - Manubens,José María, AU - Villar,María Dolores, AU - Ramos-Arroyo,María Antonia, PY - 2004/10/16/pubmed PY - 2004/12/16/medline PY - 2004/10/16/entrez SP - 251 EP - 4 JF - Medicina clinica JO - Med Clin (Barc) VL - 123 IS - 7 N2 - BACKGROUND AND OBJECTIVE: The association between the presence of the allele APOE*epsilon4 (apolipoprotein E) and sporadic Alzheimer disease (AD) has been long established. However, the possible influence of other genetic factors is still under debate. This study investigated the role of the a 1-antichymotrypsin (ACT) gene as a susceptibility factor for developing late-onset AD in the population of Navarra. PATIENTS AND METHODS: The study group included 98 patients with late-onset AD and 188 control individuals 70-71 years of age. APOE*epsilon2,*epsilon3,*epsilon4 and ACT codon -17*A,*T polymorphisms were analyzed by PCR-RFLP. Statistical analyses were performed determining the chi-square test, using 2 x 2 contingency tables and logistic regression to calculate odds ratios. RESULTS: APOE*epsilon4 allele frequency was significantly higher in AD patients than in controls (odds ratio [OR] = 3.02; 95% confidence interval [CI], 1.59-5.73; p < 0.001 in heterozygous carriers, and OR = 9.40; 95% CI, 1.84-64.43; p = 0.001 in homozygous individuals). We found no significant differences in the distribution of ACT polymorphisms between AD cases and controls. However, APOE*epsilon4 carriers had a 2.5-fold increased risk of developing AD in the presence of the ACT/AA genotype (OR = 10.13; 95% CI, 1.98-97.81; p < 0.001). The risk difference, however, did not reach statistical significance (p = 0.271). CONCLUSIONS: APOE*epsilon4 heterozygous and homozygous carriers have a 3 and 9 times higher risk, respectively, of developing AD. We could not demonstrate an effect of ACT polymorphisms as a independent risk factor for this disease; however, the ACT/AA genotype seems to act as an additional susceptibility factor, duplicating the APOE*epsilon4-associated AD risk. SN - 0025-7753 UR - https://www.unboundmedicine.com/medline/citation/15482730/[ACT/AA_polymorphism_could_duplicate_the_APOE_epsilon4_associated_Alzheimer's_disease_risk]_ DB - PRIME DP - Unbound Medicine ER -